This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
JAK Inhibitor Program (Aclaris/Rigel)
Aclaris Therapeutics, Inc.
Drug Names(s): JAK Inhibitor Program
Description: Aclaris and Rigel are collaborating to develop JAK inhibitors for the treatment of alopecia areata and other dermatological conditions.
Rigel and Aclaris
In September 2015, Aclaris Therapeutics International (ATIL), a wholly owned subsidiary of Aclaris Therapeutics, and Rigel entered into an exclusive, worldwide license agreement for the development and commercialization of specified Rigel JAK inhibitors for the treatment of alopecia areata and other dermatological conditions.
Under the license agreement, ATIL will assume responsibility for the continued development of specified Rigel JAK inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. Rigel will receive an upfront payment of $8 million, and will be eligible to receive various milestone payments of up to $90 million based on global development and multiple indications, as well as tiered royalties on any future sales of these compounds.
Partners: Rigel Pharmaceuticals, Inc.
JAK Inhibitor Program (Aclaris/Rigel) News
Additional information available to subscribers only: